Bolt Biotherapeutics, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Bolt Biotherapeutics, Inc. (BOLT) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $6.72 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-12
- Bolt Biotherapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $6.72M, a 49.03% decline from fiscal 2024.
- Bolt Biotherapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $13.19M, a 0.08% decline from fiscal 2023.
- Bolt Biotherapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $13.20M, a 14.84% decline from fiscal 2022.
- Bolt Biotherapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $15.50M, a 27.23% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $6.72M 10-K · filed 2026-03-12 | |
| 2024-12-31 | $13.19M 10-K · filed 2026-03-12 | $13.20M 10-K · filed 2025-03-24 |
| 2023-12-31 | $13.20M 10-K · filed 2025-03-24 | $15.50M 10-K · filed 2024-03-21 |
| 2022-12-31 | $15.50M 10-K · filed 2024-03-21 | $18.80M 10-K · filed 2023-03-29 |
| 2021-12-31 | $21.30M 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |